BRPI0712322A2 - compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos - Google Patents
compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos Download PDFInfo
- Publication number
- BRPI0712322A2 BRPI0712322A2 BRPI0712322-1A BRPI0712322A BRPI0712322A2 BR PI0712322 A2 BRPI0712322 A2 BR PI0712322A2 BR PI0712322 A BRPI0712322 A BR PI0712322A BR PI0712322 A2 BRPI0712322 A2 BR PI0712322A2
- Authority
- BR
- Brazil
- Prior art keywords
- amyloid
- compounds
- methods
- alzheimer
- production
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000009825 accumulation Methods 0.000 abstract 3
- 230000002490 cerebral effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000006951 hyperphosphorylation Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000007388 microgliosis Effects 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSTOS E COMBINAçõES DESTES PARA A INIBIçãO DA PRODUçãO DE BETA-AMILóIDE E MéTODOS DE USO DOS MESMOS. São fornecidos compostos que podem ser usados em combinação para o tratamento de doenças associadas com uma condição associada com o acúmulo cerebral de amilóide de Alzheimer, como doença de Alzheimer. Também são fornecidos métodos de tratamento ou de redução do risco de desenvolvimento de produção de <225>-amilóide, depósito de <225> amilóide, neurotoxicidade de <225>-amilóide (incluindo hiperfosforilação anormal de tau) e microgliose associadas com acúmulo cerebral de amilóide de Alzheimer por administração de quantidades terapeuticamente eficazes de compostos que em combinação podem diminuir a produção de <225> amilóide e a capacidade de entrada de cálcio em células. Também são fornecidos métodos para o diagnóstico de doenças associadas com acúmulo cerebral de amilóide de Alzheimer em animais ou humanos por administração de quantidades diagnosticamenue eficazes dos compostos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81912906P | 2006-07-06 | 2006-07-06 | |
| US60/819.129 | 2006-07-06 | ||
| PCT/US2007/072959 WO2008006070A2 (en) | 2006-07-06 | 2007-07-06 | Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0712322A2 true BRPI0712322A2 (pt) | 2012-02-22 |
Family
ID=38895495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0712322-1A BRPI0712322A2 (pt) | 2006-07-06 | 2007-07-06 | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080058330A1 (pt) |
| KR (1) | KR20090026275A (pt) |
| AU (1) | AU2007269090A1 (pt) |
| BR (1) | BRPI0712322A2 (pt) |
| CA (1) | CA2655029A1 (pt) |
| WO (1) | WO2008006070A2 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| HRP20140240T4 (hr) * | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US20130266663A1 (en) * | 2010-04-30 | 2013-10-10 | Arthur Brown | Sox9 inhibitors |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| KR101937782B1 (ko) | 2011-03-01 | 2019-01-11 | 파넥스트 | 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료 |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| CN103044316A (zh) * | 2013-01-23 | 2013-04-17 | 石家庄学院 | 一种以咪唑离子液体为催化剂制备1,4-二氢吡啶的方法 |
| US20150166476A1 (en) * | 2013-12-17 | 2015-06-18 | Yi-Cheng Chen | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta |
| JP6935883B2 (ja) * | 2018-07-13 | 2021-09-15 | 五稜化薬株式会社 | 蛍光画像診断の前処理方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
-
2007
- 2007-07-06 KR KR1020087029736A patent/KR20090026275A/ko not_active Withdrawn
- 2007-07-06 CA CA002655029A patent/CA2655029A1/en not_active Abandoned
- 2007-07-06 US US11/774,357 patent/US20080058330A1/en not_active Abandoned
- 2007-07-06 AU AU2007269090A patent/AU2007269090A1/en not_active Abandoned
- 2007-07-06 WO PCT/US2007/072959 patent/WO2008006070A2/en not_active Ceased
- 2007-07-06 BR BRPI0712322-1A patent/BRPI0712322A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008006070A2 (en) | 2008-01-10 |
| AU2007269090A1 (en) | 2008-01-10 |
| WO2008006070A3 (en) | 2008-03-06 |
| US20080058330A1 (en) | 2008-03-06 |
| KR20090026275A (ko) | 2009-03-12 |
| CA2655029A1 (en) | 2008-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| PH12012502079A1 (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| NZ598694A (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| MX2012006552A (es) | Agentes de enlace amiloides. | |
| BR112012028651A2 (pt) | heterociclilbenzilpirazóis substituídos e uso do mesmo | |
| DE602006014691D1 (de) | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| BR112014030325A2 (pt) | composição farmacêutica para tratar ou prevenir doença neurodegenerativa e alimento funcional | |
| MX2009013482A (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas. | |
| BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
| MA32416B1 (fr) | 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2007103683A3 (en) | Compounds for inhibiting beta-amyloid production | |
| BR112012006155A2 (pt) | função de ácido n-2-hidroxi-etil-piperazina-n´-2-etano sulfônico (hepes) em controle de dor e reversão de lesão de demielinização. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES. |